All data are based on the daily closing price as of March 20, 2026
m
Medy-Tox
086900.KQ
71.82 USD
1.21
+1.71%
Overview
Last close
71.82 usd
Market cap
472.48M usd
52 week high
149.12 usd
52 week low
70.61 usd
Target price
87.69 usd
Valuation
P/E
N/A
Forward P/E
33.0033
Price/Sales
2.9276
Price/Book Value
1.5229
Enterprise Value
481.75M usd
EV/Revenue
2.999
EV/EBITDA
35.3444
Key financials
Revenue TTM
160.64M usd
Gross Profit TTM
92.88M usd
EBITDA TTM
27.78M usd
Earnings per Share
N/A usd
Dividend
3.19 usd
Total assets
419.01M usd
Net debt
11.09M usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.